Regulation of the Cdk inhibitor p27 and its deregulation in cancer

p27 is a cell cycle inhibitor whose cellular abundance increases in response to many antimitogenic stimuli. In this review, we summarize the current knowledge on p27 function and its regulation by synthesis and by ubiquitin‐mediated degradation. Importantly, p27 degradation is enhanced in many aggressive human tumors. The frequency with which this is observed suggests that loss of p27 may confer a growth advantage to these cancers. From a practical point of view, immunodetection of p27 in tumors may prove to be useful in the assessment of prognosis and may ultimately influence the therapy of this disease. J. Cell. Physiol. 183:10–17, 2000. © 2000 Wiley‐Liss, Inc.

[1]  K. Fujisawa,et al.  Protein Kinase N (PKN) and PKN-Related Protein Rhophilin as Targets of Small GTPase Rho , 1996, Science.

[2]  A. Zeleniuch‐Jacquotte,et al.  Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. , 1999, The American journal of pathology.

[3]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[4]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[5]  T. Hunter,et al.  Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells , 1996, Nature.

[6]  M. Piris,et al.  Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. , 1997, The American journal of pathology.

[7]  G. Cooper,et al.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1 , 1997, Molecular and cellular biology.

[8]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[9]  G. Hannon,et al.  p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.

[10]  G. Landberg,et al.  Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. , 1998, Blood.

[11]  Stephen J. Elledge,et al.  SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.

[12]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[13]  J. Jones,et al.  Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. , 1996, Cancer research.

[14]  James M. Roberts,et al.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.

[15]  L. Jin,et al.  Aberrant p27kip1 expression in endocrine and other tumors. , 1997, The American journal of pathology.

[16]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[17]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[18]  M. Loda,et al.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.

[19]  T. Hunter,et al.  Dependence of Cyclin E-CDK2 Kinase Activity on Cell Anchorage , 1996, Science.

[20]  G. Bradley,et al.  Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. , 1998, The American journal of pathology.

[21]  P. Yaswen,et al.  Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells , 1997, Molecular and cellular biology.

[22]  Andrea C. Carrano,et al.  SKP 2 is required for ubiquitin-mediated degradation of the CDK inhibitor p 27 , 1999 .

[23]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[24]  R. Kerbel,et al.  TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. , 1996, Oncogene.

[25]  A. Murray,et al.  Creative blocks: cell-cycle checkpoints and feedback controls , 1992, Nature.

[26]  W. Krek,et al.  p45 SKP2 promotes p27 Kip1 degradation , 1999 .

[27]  C. Sherr G1 phase progression: Cycling on cue , 1994, Cell.

[28]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[29]  S. Elledge,et al.  A family of mammalian F-box proteins , 1999, Current Biology.

[30]  D. Schiffer,et al.  Proteasome-dependent degradation of p27/kip1 in gliomas. , 1999, Journal of neuropathology and experimental neurology.

[31]  T. Hunt,et al.  The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. , 1996, The EMBO journal.

[32]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.

[33]  A. Kumar,et al.  An additional role for the F-box motif: gene regulation within the Neurospora crassa sulfur control network. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Kobayashi,et al.  pl9 skp1 and p45 skp2 are essential elements of the cyclin A-CDK2 S phase kinase , 1995, Cell.

[35]  W. Zwerschke,et al.  Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. , 1996, Oncogene.

[36]  L. Hengst,et al.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells , 1994, Molecular and cellular biology.

[37]  H. Sasano,et al.  Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  M. Pagano,et al.  Enhanced Ribosomal Association of p27Kip1 mRNA Is a Mechanism Contributing to Accumulation during Growth Arrest* , 1997, The Journal of Biological Chemistry.

[39]  N. Takuwa,et al.  Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts , 1997, Molecular and cellular biology.

[40]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[41]  S. Shousha,et al.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Slingerland,et al.  The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. , 1999, Annual review of medicine.

[43]  A. Robles,et al.  Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[44]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[45]  M. Monden,et al.  Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.

[46]  W. Panje,et al.  Prognostic Significance of p27 Expression in Carcinoma of the Oral Cavity and Oropharynx , 1999, The Laryngoscope.

[47]  M. Raff,et al.  Accumulation of the cyclin‐dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation , 1997, The EMBO journal.

[48]  O. Hazeki,et al.  Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. , 1995, Trends in biochemical sciences.

[49]  M. Pagano,et al.  Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation , 1997, Leukemia.

[50]  M. Kawada,et al.  Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway , 1997, Oncogene.

[51]  Y. Yatabe,et al.  p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. , 1998, Cancer research.

[52]  S. Groshen,et al.  Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.

[53]  L. Hengst,et al.  A cell cycle-regulated inhibitor of cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  G. Cattoretti,et al.  Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.

[55]  Yanping,et al.  Loss of the Cyclin-dependent Kinase Inhibitor 27Kq Protein in Human Prostate Cancer Correlates with Tumor Grade’ , 2005 .

[56]  M. Kitagawa,et al.  Down-regulation of p27 Kip1 by Two Mechanisms, Ubiquitin-mediated Degradation and Proteolytic Processing* , 1999, The Journal of Biological Chemistry.

[57]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[58]  B. Amati,et al.  Growth arrest by the cyclin‐dependent kinase inhibitor p27Kip1 is abrogated by c‐Myc. , 1996, The EMBO journal.

[59]  G. Landberg,et al.  Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation , 1999, Oncogene.

[60]  F. Shepherd,et al.  Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. , 1999, Cancer research.

[61]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[62]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[63]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.

[64]  S. Elledge,et al.  How the Cyclin Became a Cyclin Regulated Proteolysis in the Cell Cycle , 1999, Cell.

[65]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[66]  G. Landberg,et al.  Prognostic significance of p27Kip1 expression in colorectal cancer: a clinico‐pathological characterization , 1999, The Journal of pathology.

[67]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[68]  R. Assoian,et al.  Anchorage-dependent Cell Cycle Progression , 1997, The Journal of cell biology.

[69]  Juan F. García,et al.  Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. , 1999 .

[70]  Ludger Hengst,et al.  G1 control in mammalian cells , 1994, Journal of Cell Science.

[71]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[72]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[73]  M. Pagano,et al.  Cell cycle regulation by the ubiquitin pathway , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[74]  W. Ansorge,et al.  Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes , 1997, Oncogene.

[75]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[76]  S. Semba,et al.  Reduced Expression of Cyclin–dependent Kinase Inhibitor p27Kipl Is Associated with Advanced Stage and Invasiveness of Gastric Carcinomas , 1997, Japanese journal of cancer research : Gann.

[77]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[78]  R. Kerbel,et al.  Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.

[79]  A. Koff,et al.  Cell-Free Degradation of p27kip1, a G1 Cyclin-Dependent Kinase Inhibitor, Is Dependent on CDK2 Activity and the Proteasome , 1999, Molecular and Cellular Biology.

[80]  M. Roussel,et al.  Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. Palazzo,et al.  Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. , 1999, Cancer research.

[82]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[83]  Andrea C. Carrano,et al.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. , 1999, Genes & development.

[84]  T. Tamiya,et al.  Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[86]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[87]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[88]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[89]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[90]  H. Saito,et al.  Expression of protein p27 is associated with progression and prognosis in laryngeal cancer , 1999, The Laryngoscope.

[91]  T. Visakorpi,et al.  Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.

[92]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[93]  J. Bartek,et al.  Abrogation of p27Kip1 by cDNA Antisense Suppresses Quiescence (G0 State) in Fibroblasts* , 1996, The Journal of Biological Chemistry.

[94]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[95]  O. Cohen,et al.  Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[96]  S. Dedhar,et al.  Overexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression* , 1997, The Journal of Biological Chemistry.

[97]  James M. Roberts,et al.  Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein , 1996, The Journal of cell biology.

[98]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[99]  T. Hunter,et al.  Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells , 1998, Oncogene.

[100]  M. Tyers,et al.  Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. , 1998, Trends in genetics : TIG.

[101]  Hong Sun,et al.  p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.

[102]  James M. Roberts,et al.  Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors , 1996, Cell.

[103]  M. Dictor,et al.  Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. , 2000, Cancer.

[104]  D. Schiffer,et al.  p27/kip1 expression in human astrocytic gliomas , 1997, Neuroscience Letters.

[105]  James M. Roberts,et al.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.

[106]  M. Loda,et al.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.

[107]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[108]  M. Vidal,et al.  Identification of a family of human F-box proteins , 1999, Current Biology.